期刊文献+

脾氨肽降低婴幼儿毛细支气管炎后哮喘发病率的临床观察 被引量:3

Clinical Efficacy of Spleen Aminopeptide in Reducing the Incidence of Asthma in Infants with Bronchiolitis
下载PDF
导出
摘要 目的:探讨脾氨肽降低婴幼儿毛细支气管炎后哮喘发病率的效果。方法:将2010年5月至2012年10月166例毛细支气管住院患儿随机分成干预组与对照组,两组均予常规治疗后痊愈出院。对照组出院后不予药物预防治疗,干预组在出院后口服脾氨肽预防治疗2个月。比较两组患儿1年内支气管哮喘的发病率、临床观察结束(出院1年后)对血清总免疫球蛋白E(IgE)及外周血嗜酸性粒细胞(EOS)计数。结果:干预组87例患儿发生哮喘10例(11.49%),对照组79例患儿发生哮喘27例(34.17%);1年后干预组患儿的IgE与EOS计数比对照组患儿降低更明显,差异均有统计学意义(P<0.05或P<0.01)。结论:脾氨肽在预防婴幼儿毛细支气管炎发展成哮喘方面有肯定的作用,能明显降低哮喘发病率。 OBJECTIVE: To investigate the efficacy of spleen aminopeptidase in reducing the incidence of asthma in infants with bronchiolitis. METHODS: From May 2010 to October 2012, a total of 166 infants with bronchiolitis were randomly assigned to either intervention group or control group. After treatment with routine therapy, all the patients were discharged from hospital. Then only the intervention group was preventively administered with oral spleen aminopeptidase for 2 months. The incidence of bronchial asthma in the two groups within one year were followed, and the total serum immunoglobulin E (IgE) level and peripher- al blood eosinophils (EOS) count were recorded after completion of clinical observation (at 1 year after being discharged from hos- pital). RESULTS: 10 cases in the intervention group (11.49%) versus 87 cases (34.17%) in the control group developed asthma. At 1 year after being discharged from hospital, the reduction in lgE level and peripheral blood eosinophils (EOS) count in the inter- vention group were more significant than in the control group, showing statistically significant differences (P 〈 0.05 or P 〈 0.01 ). CONCLUSIONS: Spleen aminopeptidase has positive preventive efficacy against asthma in the infant for it can significantly reduce the incidence of asthma.
出处 《中国医院用药评价与分析》 2014年第9期786-788,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 脾氨肽 婴幼儿 毛细支气管炎 哮喘 发病率 Spleen aminopeptidase Infant Bronchiolitis Asthma Incidence
  • 引文网络
  • 相关文献

参考文献11

二级参考文献78

  • 1齐岩,孟丽红.匹多莫德治疗儿童反复呼吸道感染95例疗效分析[J].中国中西医结合儿科学,2007(5):375-377. 被引量:18
  • 2邱培全,黄东秀.干扰素联合维生素AD治疗小儿反复呼吸道感染34例疗效及免疫功能观察[J].新乡医学院学报,2005,22(1):41-43. 被引量:23
  • 3费云敏.匹多莫德口服液治疗小儿反复呼吸道感染临床观察[J].吉林医学,2006,27(7):781-781. 被引量:14
  • 4张梓荆 盛锦云 等.全国小儿呼吸道疾病学术会议纪要[J].中华儿科杂志,1988,26(1):40-40.
  • 5Leung TF, Wong GW. The Asian side of asthma and allergy. Curr Opin Allergy Clin Immunol,2008,8 (5) :384-390.
  • 6Piippo-Savolainen E, Korppi M. Wheezy babies wheezy adults? Review on long-term outcome until adulthood after early childhood wheezing. Aeta Paediatr,2008,97 ( 1 ) :5-11.
  • 7Jackson D J, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in highrisk children. Am J Respir Crit Care Med,2008,178 (7) :667- 672.
  • 8Sigurs N, Bjarnason R, Sigurbergsson F, et al. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med, 2000,161(5) :1501-1507.
  • 9Glezen WP,Taber LH,Frank AL,et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child, 1986,140 ( 6 ) : 543-546.
  • 10Robinson RF. Impact of respiratory syncytial virus in the United States. Am J Health Syst Pharm, 2008,65 ( 23 Suppl 8 ) : S3-S6.

共引文献3411

同被引文献25

引证文献3

二级引证文献9

相关主题

;
使用帮助 返回顶部